Rightsmile, Inc. (RIGH)

[planetaryfuture]

WHO Speculation Indicates Cannabis Schedule-Change .....

This same information has been alleged before and makes the future look brighter toward ending Cannabis prohibition .....

A note of interest to Cannabis Investors : A number of people likely recall the Federal CBD patent is set to expire during 2019 ..... which should add a boost of momentum toward legalization .....

As far as I can tell $RIGH is not bvurdened with toxic debt and has not been diluting "paper" into the Market ..... Stuck in a .0001-.0002 share price trading groove for many years ..... so what's the holdup ? ..... I keep repeating ..... I believe it would have to be the Federally illegal designation of Cannabis which appears to be in a process of legislative transition ..... However slow and stalled by elite special interests !!! .....

Can one afford to sober-up for a moment and recognize the FDA has a longstanding history of saturating the Market with toxic profitable drugs ? ..... whenever the "producer" can afford to pay a premium ..... Why are so few willing to admit the FDA looks about as trustworthy as a $3 bill ? ..... If CBD could legally be added to foods ..... millions of people would likely get much healthier and then have a vastly reduced need for healthcare ..... Saving our Great American citizens and the government potentially "billions of dollars" ..... Unfortunately ..... Trump gives this issue seemingly little to no thought when he just might be poised to prevail as the "Universal Hero of Humanity" .....

How Alleged WHO Recommendations Would Affect International Cannabis Markets

February 11, 2019 ..... by New Frontier Data

An anticipated recommendation by the World Health Organization (WHO) calling for the international rescheduling of “marijuana” and derivative products is poised to be a watershed moment with implications to be observed throughout global markets.

If an unconfirmed leak of a WHO document reported February 1 by a cannabis legalization activist and journalist* is accurate, United Nations (UN) global health experts next month will advocate for whole-plant marijuana and cannabis resin to be rescheduled from a Schedule IV classification (the most restrictive as defined within a 1961 international drug convention), and for delta-9-tetrahydrocannabinol (THC) and related isomers to be completely removed from a separate 1971 international drug treaty.

The proposed rescheduling would de-emphasize marijuana and resins to Schedule I (the lowest level of international restrictions), and would remove altogether CBD having THC levels below 0.2%. Cannabis tinctures and extracts would also be designated as Schedule I. (Note: That designation contrasts with classification under the U.S. Controlled Substances Act of 1970 [CSA], in which Schedule I is the most restrictive level).

The rescheduling of cannabis products would accelerate the pace of global cannabis reform. Currently, more than 60 countries allow for some form of legalized medical, adult-use, or industrial cannabis production or research activities. Countries which have previously resisted reform efforts for fear of international repercussions would be encouraged toward developing domestic cannabis industries and expanding international trade between newly opened markets.

The global hemp industry would also expand in both scope and influence. Based on data in The Global State of Hemp 2019 Industry Outlook (released tomorrow), the de-scheduling of hemp-derived CBD would lend economic accelerant to a market already afire: As detailed in the report, global CBD sales in 2018 are estimated beyond $800 million, with the overall global hemp market forecast to expand at a 17.5% rate through 2020. By removing industrial hemp-based CBD products from any scheduling, look for the pace of global growth to quicken, and for more countries to utilize hemp to provide economic development.

The proposed changes by the WHO would also significantly affect the U.S. medical, adult-use, and industrial markets. By having the world’s leading health organization endorse health-related benefits to cannabis, U.S. regulators, legislators, and other policymakers would be hard-pressed to justify the current CSA scheduling, which asserts there being no medicinal value in cannabis and continues a policy that prioritizes the most punitive penalties for cannabis violations. Pressure for legislative and regulatory reform is already underway given Canada’s nationwide program and Mexico’s judicial repeal of prohibition.

That noted, much remains to be decided: Member states of the UN Commission on Narcotic Drugs (CND) originally expected to receive the recommendations from WHO’s Expert Committee on Drug Dependence (ECDD) in December 2018, before they were delayed to CND’s annual meeting next month. Now, however, there is conjecture that the ECDD recommendations may not be presented until sometime in 2020 to offer additional time for their consideration by member states.

https://www.benzinga.com/markets/cannabis/19/02/13138747/how-alleged-who-recommendations-would-affect-international-cannabis-?mc_cid=b32741c1ef&mc_eid=4e4291d709


Best Wishes